Drugs / Norzyme
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01587534 | Oct 2011 → Dec 2014 | malignant pancreatic neoplasm | National Cancer Center, Korea | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT01228643 | Jun 2007 → Nov 2011 | chronic renal failure syndrome | Azidus Brasil | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05112328 | Jul 2021 → Jul 2026 overdue | exocrine pancreatic insufficiency | Seoul National University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norzyme | “Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.” NCT01228643 ↗ |
| Modality | Protein / enzyme biologic | “a formulation containing enzyme pancreas” NCT01228643 ↗ |
| Route | Oral | “Patients took two capsules each three times daily during main meals and one capsule each up to three times daily when having between-meal snacks.” PMID 27618657 ↗ Sep 2016 |